UniProt Q8TD19 · PDB · AlphaFold · Substrate: MBP · Clone: Catalytic (aa 347-732)high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Fostamatinib | 100.0% | 0.0% | 96.74 | 0.613 |
| 2 | Dabrafenib | 99.7% | 0.3% | 94.74 | 0.633 |
| 3 | Pacritinib | 78.7% | 21.4% | 88.64 | 0.452 |
| 4 | Axitinib | 76.5% | 23.5% | 93.23 | 0.688 |
| 5 | Crizotinib | 72.1% | 27.9% | 91.39 | 0.581 |
| 6 | Brigatinib | 70.7% | 29.3% | 82.96 | 0.513 |
| 7 | Fedratinib | 61.3% | 38.7% | 96.21 | 0.576 |
| 8 | Midostaurin | 59.9% | 40.1% | 78.64 | 0.500 |
| 9 | Defactinib | 59.0% | 41.0% | 92.68 | 0.450 |
| 10 | Avapritinib | 51.2% | 48.8% | 97.73 | 0.644 |
| 11 | Vemurafenib | 45.8% | 54.2% | 96.49 | 0.598 |
| 12 | Ripretinib | 41.5% | 58.5% | 92.95 | 0.674 |
| 13 | Ponatinib | 36.9% | 63.1% | 78.23 | 0.534 |
| 14 | Sorafenib | 26.9% | 73.1% | 96.72 | 0.776 |
| 15 | Pralsetinib | 25.4% | 74.6% | 93.43 | 0.643 |
| 16 | Ruxolitinib | 24.3% | 75.7% | 98.25 | 0.592 |
| 17 | Bosutinib | 24.2% | 75.8% | 87.22 | 0.555 |
| 18 | Nintedanib | 22.4% | 77.6% | 90.23 | 0.608 |
| 19 | Regorafenib | 20.8% | 79.2% | 95.99 | 0.719 |
| 20 | Netarsudil | 20.2% | 79.8% | 93.22 | 0.676 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.04
- Epithelial log2(TPM+1): 4.71
- Fold change: 0.33
- Status: No significant change
High-confidence drugs
- Fostamatinib — inh 100.0% · KISS 43.17
- Dabrafenib — inh 99.7% · KISS 42.55
- Axitinib — inh 76.5% · KISS 17.59
Selectivity landscape vs inhibition on NEK9
Each point is one of the 92 approved drugs; color = inhibition % on NEK9.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…